We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Risk Factor Identified for Life-Threatening Disease in Premature Infants

By LabMedica International staff writers
Posted on 03 Feb 2014
Many premature infants suffer a life-threatening bowel infection called necrotizing enterocolitis (NEC), and a marker has been identified in those infants who are at risk for the infection.

Since thrombocytopenia and bowel ischemia are consistent findings in advanced NEC, two potential biomarkers, reticulated platelets (RP) and intestinal alkaline phosphatase (iAP), were investigated. More...


Scientists at Loyola University Medical Center (Maywood, IL, USA) prospectively enrolled 177 infants born at less than 32 weeks' gestation and who were less than 1,500 grams in weight, from 2009 to 2012. Blood samples were collected from these infants within 72 hours of birth and weekly for four weeks to measure reticulated platelets (RP) and intestinal alkaline phosphatase (iAP). The percentage of reticulated platelets was determined by flow cytometry and serum iAP levels were determined by gel electrophoresis.

Of the 177 infants, 15 (8.5%) developed NEC and of these, 93% had low RP levels and 60% had high iAP. Those infants with low RP levels were significantly more likely to develop NEC while those with high iAP showed a similar trend. The study found that infants who would go on to develop NEC had significantly higher iAP levels at week four. While classically NEC occurs at week three of life, feeds of infants in the neonatal intensive care unit are advanced slowly and typically not started until near the end of the first week. The later initiation of feeds in the preterm infants in the study might be a reflection of them being extremely low birthweight infants (birthweight less than 1,000 g) and unstable at birth, delaying the onset of enteral feeds.

The authors concluded that as NEC affects up to 10% of very low birthweight infants, an already vulnerable population, it is important to discover reliable tests to detect those infants in this subpopulation who are most at risk of developing NEC in order to work towards prevention. Currently, no one test exists that can predict NEC; however, the team’s study suggests that the findings of low reticulated platelets and a high iAP may be useful in identifying those preterm infants at risk of NEC. Jonathan Muraskas, MD, the senior author, said, “Decreased reticulated platelets serve as a sensitive indicator for NEC onset. Further research also may find that infants with elevated iAP levels may be at risk.” The study was published online in the November 2013 issue of the Journal of Pediatric Surgery.

Related Links:

Loyola University Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Immunofluorescence Analyzer
IFA System
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.